Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV.

@article{Lvi2016ConversionTR,
  title={Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV.},
  author={Francis A L{\'e}vi and Val{\'e}rie Boige and Mohamed Hebbar and Dayna Smith and C{\'e}line Lep{\`e}re and C. Focan and Abdoulaye Karabou{\'e} and Rosine Guimbaud and Carlos Vitor de Alencar Carvalho and Salvatore Tumolo and Pasquale F Innominato and Y Ajavon and Stuephanie Truant and Denis Castaing and Tom De Baere and Francis Kunstlinger and Mohamed Bouchahda and Mona Afshar and Ph Rougier and Ren{\'e} A Adam and Michel P Ducreux},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2016},
  volume={27 2},
  pages={267-74}
}
BACKGROUND Systemic chemotherapy typically converts previously unresectable liver metastases (LM) from colorectal cancer to curative intent resection in ∼15% of patients. This European multicenter phase II trial tested whether hepatic artery infusion (HAI) with triplet chemotherapy and systemic cetuximab could increase this rate to 30% in previously treated patients. PATIENTS AND METHODS Participants had unresectable LM from wt KRAS colorectal cancer. Main non-inclusion criteria were advanced… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 6 times over the past 90 days. VIEW TWEETS
9 Citations
31 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 31 references

Randomized trial of TAS-102 for refractory metastatic colorectal cancer

  • RJ Mayer, E Van Cutsem, A Falcone
  • N Engl J Med
  • 2015

ESMO Guidelines Working Group Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

  • E Van Cutsem, A Cervantes, B Nordlinger, D. Arnold
  • Ann Oncol
  • 2014
1 Excerpt

CORRECT Study Group Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

  • A Grothey, E Van Cutsem, A Sobrero
  • Lancet
  • 2013

Similar Papers

Loading similar papers…